Medication Management Plan for Today's Visit
Start amlodipine 5 mg daily immediately, discontinue hydrochlorothiazide, switch from Rybelsus to Ozempic 0.25 mg subcutaneously weekly (with plan to increase to 0.5 mg after 4 weeks if tolerated), continue Farxiga 10 mg daily, initiate Senna and Colace for constipation, and defer thyroid medication restart until next visit after reassessing thyroid function. 1, 2
Blood Pressure Management
Discontinue Hydrochlorothiazide Today
- Stop hydrochlorothiazide immediately because thiazide diuretics increase dehydration risk in CKD stage 3, worsen volume depletion, and can precipitate acute kidney injury—especially problematic during Ramadan fasting. 3
- Thiazides combined with SGLT2 inhibitors (Farxiga) create additive volume depletion risk and can trigger severe electrolyte disturbances including hypokalemia, which paradoxically increases rhabdomyolysis risk when combined with other medications. 3
Start Amlodipine 5 mg Daily
- Begin amlodipine 5 mg once daily this morning as the preferred antihypertensive in this patient with diabetes, CKD, and recent hyperkalemia (now resolved). 2
- Amlodipine is ideal because it does not affect potassium levels, provides 24-hour blood pressure control, and has proven efficacy in diabetic patients with CKD when combined with RAAS inhibition. 2
- In diabetic patients with hypertension and CKD, amlodipine-based regimens achieve blood pressure goals <130/80 mmHg in approximately 62% of patients within 18 weeks. 2
Future RAAS Inhibitor Consideration
- Plan to restart a RAAS inhibitor (ACE inhibitor or ARB) at the next visit once blood pressure response to amlodipine is assessed and potassium remains stable <5.0 mEq/L. 4
- Do not avoid RAAS inhibitors long-term despite the recent hyperkalemia episode—continuation of RAAS blockade is essential for cardio-renal protection in diabetic CKD. 4
Diabetes Management
Switch from Rybelsus to Ozempic
- Discontinue Rybelsus 7 mg today and start Ozempic 0.25 mg subcutaneously once weekly to address severe constipation (4 days without bowel movements) while maintaining GLP-1 receptor agonist therapy. 1, 5
- The subcutaneous formulation has superior bioavailability compared to oral semaglutide and provides additional cardiovascular and renal protection in high-risk diabetic patients with atherosclerotic disease and CKD. 5
- Increase to Ozempic 0.5 mg weekly after 4 weeks if the 0.25 mg dose is tolerated without recurrent dizziness (which occurred during her previous trial 4-5 months ago). 1
Address Previous Dizziness Concern
- The prior dizziness with Ozempic 0.25 mg may have been related to volume depletion from concurrent hydrochlorothiazide use—now discontinued—rather than semaglutide itself. 1
- Monitor for orthostatic hypotension at follow-up visits, especially during the first 4 weeks, as GLP-1 agonists can cause dehydration through nausea and reduced oral intake. 1
Continue Farxiga (Dapagliflozin)
- Continue Farxiga 10 mg daily without interruption as SGLT2 inhibitors provide critical cardio-renal protection in diabetic CKD stage 3 and reduce hyperkalemia risk. 6, 7
- SGLT2 inhibitors should be initiated and continued in patients with eGFR ≥20 mL/min/1.73 m², regardless of diabetes control, for renal and cardiovascular protection (Grade 1A recommendation). 6
- Farxiga modestly lowers serum potassium, which supports safe reintroduction of RAAS inhibitors in the future. 7
- Do not discontinue if eGFR drops 2-6% (≈2 mL/min/1.73 m²) in the first 2 months—this hemodynamic dip is expected and reversible. 6
Constipation Management
- Start Senna 8.6 mg 1-2 tablets at bedtime and Colace (docusate) 100 mg twice daily to manage GLP-1 agonist-induced constipation. 1
- Counsel on increasing dietary fiber (chia seeds, vegetables) and maintaining hydration with at least 8-10 glasses of water daily, distributed appropriately around Ramadan fasting hours. 1
- Constipation is a common adverse effect of all GLP-1 agonists; switching to subcutaneous formulation may reduce but not eliminate this side effect. 1
Chronic Kidney Disease Management
Nephrology Follow-Up
- Ensure nephrology appointment on the scheduled date is kept to reassess CKD stage 3 progression and optimize nephroprotective therapy. 6
- The combination of Ozempic and Farxiga provides synergistic renal protection—GLP-1 agonists reduce albuminuria and slow eGFR decline in diabetic nephropathy. 8, 5
Hydration During Ramadan
- Counsel on maintaining adequate hydration with her current regimen (4 glasses morning, 4-5 glasses after breaking fast, 4 glasses evening) to prevent volume depletion, especially with SGLT2 inhibitor use. 6
- SGLT2 inhibitors increase osmotic diuresis; dehydration risk is elevated during fasting periods and can precipitate acute kidney injury. 6
Monitor for Expected eGFR Changes
- Recheck basic metabolic panel in 1-2 weeks after starting Ozempic to assess potassium and creatinine stability. 6, 4
- An acute eGFR decline of 2-6% is expected with SGLT2 inhibitors and should not trigger discontinuation unless creatinine rises >30% from baseline. 6
Hyperkalemia Prevention
Current Status and Monitoring
- Potassium has normalized since discontinuing losartan—this supports that the hyperkalemia was medication-induced rather than due to advanced CKD. 4
- Recheck potassium in 1 week after medication changes, then every 4 months once stable. 4
SGLT2 Inhibitor Benefit
- Continuing Farxiga reduces hyperkalemia risk by 26% compared to DPP-4 inhibitors in CKD patients with diabetes (hazard ratio 0.74). 7
- This potassium-lowering effect will facilitate safe reintroduction of RAAS inhibitors at the next visit. 4, 7
Future RAAS Inhibitor Reintroduction
- When restarting an ACE inhibitor or ARB at the next visit, check potassium 1 week after initiation, then monthly for 3 months, then every 4 months. 4
- Do not discontinue RAAS inhibitors if potassium rises to 5.0-5.5 mEq/L—instead, consider adding a potassium binder (patiromer 8.4 g daily or sodium zirconium cyclosilicate) to maintain cardio-renal protection. 4
Hypothyroidism Management
Defer Thyroid Medication Today
- Do not restart thyroid medication today—wait until thyroid function tests (TSH, free T4) are obtained at the next visit to determine appropriate levothyroxine dosing. 1
- Hypothyroidism can worsen constipation, but addressing this after GLP-1 agonist switch and laxative initiation allows clearer assessment of each intervention's effect.
Medication Safety Counseling
Ozempic Administration
- Inject Ozempic subcutaneously once weekly on the same day each week, in the abdomen, thigh, or upper arm. 9
- Take on an empty stomach or with food—unlike Rybelsus, subcutaneous semaglutide has no food restrictions. 1, 9
- If a dose is missed, administer within 5 days; if >5 days have passed, skip and resume the regular schedule. 9
Thyroid Cancer Warning
- Counsel that semaglutide carries a black box warning for medullary thyroid carcinoma risk—discontinue immediately if neck mass, dysphagia, or persistent hoarseness develops. 1
- Do not use if personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). 1
Pancreatitis Warning
- Stop Ozempic and seek emergency care if severe, persistent abdominal pain develops (with or without vomiting), as acute pancreatitis is a serious adverse effect. 1
Hypoglycemia Risk
- Risk of hypoglycemia is low with Ozempic monotherapy, but monitor for symptoms (dizziness, sweating, confusion) given her uncontrolled diabetes and potential for improved glycemic control. 1
Dehydration Prevention
- Drink fluids consistently throughout non-fasting hours to prevent dehydration-related kidney injury, especially with combined SGLT2 inhibitor and GLP-1 agonist use. 1
- Nausea, vomiting, or diarrhea from Ozempic can cause volume depletion—contact provider if these symptoms persist >24 hours. 1
Follow-Up Plan
Return Visit Timing
- Schedule return visit in 4 weeks to assess:
Laboratory Monitoring
- Order for next visit: basic metabolic panel (potassium, creatinine, eGFR), TSH, free T4, hemoglobin A1c 4